RU2536292C1 - Method for reducing individual's biological age - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for reducing an individual's biological age. That is ensured by administering the Transfer-factor immune corrector 5 times a week for at least 6 weeks in a dose of 3-10 capsules a day in a combination with the hypoxic exposure in a cyclic-fractionation mode according to the scheme individually prescribed by the Stange's test results.

EFFECT: using this method provides reducing the age-related changes in the individuals by recovering a high level of tissue self-maintenance and optimising the body system functions that enables reducing the biological age by 9 years on the average.

2 cl, 2 tbl, 4 ex

Description

The invention relates to medicine and more specifically relates to a method of reducing the biological age of a person (rejuvenation of the body).

The active aging of the population of developed countries, registered since the end of the 20th century and expressed in a significant increase in the proportion of elderly people, served as a serious incentive to increase the activity of studying the causes and mechanisms of aging, as well as to search for methods of rejuvenating the body. Living in an unfavorable environment of megacities, an unfavorable ecological situation, harmful addictions and an unhealthy lifestyle lead to a breakdown of the body's adaptation mechanisms and its accelerated wear. The functional reserves of the body, responsible for the health and compliance of a person with his natural (biological) age, are chronically depleted. This causes fatigue, stress and depression, against which the majority of ailments arise and the aging process of the body begins to accelerate.

That is why, when in adverse environmental conditions the human body is not able to withstand the negative effects of the external environment, including infectious pathogens, the use of methods to increase the nonspecific and immunological resistance of the human body to these factors becomes especially relevant.

There is a method of normobaric hypoxytherapy, which is a radical and simultaneously controlled means of increasing nonspecific resistance of the body due to adaptation not only to oxygen deficiency, but also to a number of other environmental factors, in particular, resistance to infections, physical stress, desynchronosis is developed (Strelkov R .B., Chizhov A.Ya. Intermittent normobaric hypoxia in prevention, treatment and rehabilitation. - Yekaterinburg: Ural worker, 2001. - 400 p. RU, A, 2197280, RU, A, 2266142 SU, A, 1264949). A feature of hypoxic stimulation is the optimal combination of urgent adaptation reactions with the long-term restructuring of the energy-supplying systems of the body. And as a result, an increase in the nonspecific resistance of the organism, which is based on structural and functional changes that are exclusively physiological, genetically determined. The method of intermittent normobaric hypoxic stimulation does not conflict with other therapeutic and prophylactic effects, including allopathic, homeopathic, surgical, etc. However, studies of the effect of hypoxic effects on the functional parameters of the human body have not revealed a significant decrease in biological age (Strelkov RB, Chizhov AY Intermittent normobaric hypoxia in prevention, treatment and rehabilitation. - Yekaterinburg: Ural Worker, 2001. - 400 p.).

Currently, in addition to the classical ideas about the use of immunomodulators with a geroprophylactic effect, domestic scientists have developed ideas about lymphocytes as regulators of the growth and proliferation of somatic cells proper (V.I. Dontsov, V.N. Krutko, A.A. Podkolzin, Fundamental mechanisms of geroprophylaxis, Moscow: Bioinformservice, 2002, 414 pp.). It is known that the central mechanism of aging of tissue self-renewing by cell division is associated with a decrease in cell growth potential: a decrease in the rate of physiological regeneration. Thus, it becomes possible to use immunotropic drugs to restore a high level of tissue self-renewal, which decreases sharply with age.

A known method of reducing the biological age of a person (rejuvenation of the body), disclosed in patent RU, A, 2404784, published 22.11.2010. The method consists in the fact that in order to reverse age-related changes, the patient is given the Transfer Factor (TF) immunocorrector obtained from colostrum of cows and restores a number of indicators of immunity, reduced as a result of various reasons, at a dose of 1-3 capsules per day, based on weight 60-80 kg, 5 days a week for 6 weeks.

Using the known method gives a decrease in biological age of not more than 4.4 years. An increase in the administered dose of immunocorrector over 3 capsules per day is not effective and does not lead to an additional decrease in biological age.

The basis of the invention is the task of expanding the arsenal of means and methods of rejuvenating the body, creating such a method of rejuvenating the body, which would achieve a decrease in biological age by a larger amount than when using the well-known, in particular, by increasing the efficiency of the immunotropic drug “Transfer factor "Used to reduce the biological age of a person.

The result is achieved due to the fact that in the method of reducing the biological age, in which the immunocorrector "Transfer factor" is administered five days a week for at least 6 weeks, according to the invention, the immunocorrector is administered in combination with hypoxic exposure in a cyclically fractionated mode according to the scheme, individually selected based on the parameters of the Stange test, at a dose of 3-10 capsules per day.

The method is carried out using a hypoxic gas mixture (GHS) with a concentration of O _{2 of} not less than 9% and not more than 16%.

The method provides a reduction in age-related changes in people by restoring a high level of tissue self-renewal and optimizing the functioning of the body systems, as well as increasing the nonspecific resistance of the body. By combining the administration of the Transfer Factor immunocorrector with hypoxic exposure in a cyclically fractionated mode, it was possible to increase the effectiveness of the immunocorrector, as well as increase its effective dose, which ultimately reduced the biological age of patients by an average of 9.0 years.

The effect of the course of therapy is proved by the control of aging indicators - biological age, in individuals before and after the course of therapy.

The method is as follows.

In accordance with the indications and contraindications according to the methodological recommendations of the Ministry of Health of the Russian Federation (Normobaric hypoxytherapy. - M., 2001. Vol. 2-e., Immunorehabilitation for infectious-inflammatory and somatic diseases using Transfer factors. - M., 2004) were selected 2 groups of patients from among the residents of Moscow - the group "Transfer factor in combination with hypoxic exposure" (experimental group) and the group "Transfer factor" (control group).

A total of 71 people were examined, aged 46 to 74 years, twice (before and after the course of therapy).

The control group included 41 people aged 49 to 74 years (average age 62.8 ± 0.9), who were prescribed classic TF 3 times a day, one capsule with meals (at least 600 mg TF per day) 5 days a week for 6 weeks.

In the experimental group - 30 people, the average calendar age in the group was 60.2 ± 1.2 years (from 46 to 73 years). In this group, the subjects received the “Transfer Factor” 3 times a day, one capsule (at least 600 mg per day) after eating, and exposure to a gas hypoxic mixture of oxygen and nitrogen with an oxygen content of 9% to 16%, in a cyclic fractionated mode using the "Top" apparatus once a day according to the scheme individually selected based on the Stange test. The procedure was repeated daily five days a week for 6 weeks.

To assess individual rates of development, including the determination of premature aging, the category of biological age was used.

The main manifestations of biological age (BV) during aging are violations of the most important life functions and a narrowing of the range of adaptive potential, the occurrence of diseases and an increase in the likelihood of death or a decrease in the duration of life ahead. Each of them reflects the course of biological life time and the associated increase in biological age. In Russia, the so-called Kiev method for determining BV [Chebotarev D.F. P / ed. Biological age, heredity and aging. Yearbook "Gerontology and Geriatrics". Kiev. 1984], which is a typical linear regression model of BV and includes the following set of indicators.

1. Blood pressure (BP - mmHg): systolic blood pressure (BPA), diastolic blood pressure (BPD) - are measured according to the generally accepted method using the Riva-Rocci apparatus or similar electronic and other devices, on the right hand, in position sitting, twice with an interval of 5 min. The smallest result of the two measurements is taken into account. For the selected values of ADS and ADD, pulse arterial pressure (ADP) is calculated by the formula

ADP = ADS-ADD. Test measurement of blood pressure is always carried out at the beginning of the entire battery of tests.

2. Pulse wave velocity (SPV - m / s): pulse wave propagation velocity through elastic type arterial vessels (SPVe) in the carotid artery - femoral artery and muscle type (SPVm) in the carotid artery - radial artery section.

3. Vital lung capacity (VC) is measured (in ml) in a sitting position, 2 hours after a meal, on any spirometer. Two measurements are taken, the maximum result is taken.

4. Holding the breath (ZD - s) after deep exhalation (or inhalation) is measured twice with an interval of 5 minutes using a stopwatch.

5. Accommodation (A - diopters) is determined for the leading eye by finding the nearest point of clear vision when reading the font from the Sivtsov tables under the conditions of correction of ametropia and presbyopia. An approximate determination of the distance to the nearest point of clear vision (in which the text is still clearly distinguishable) is possible using a ruler or centimeter, measuring the distance L (where L is the distance in mm) from the lower edge of the eye’s orbit to the sheet with text printed in Times New font Roman, 11 pixels in size. The amount of accommodation is calculated further by the formula A = 1000 / L.

6. Static balancing (SB - s) is determined when the subject is standing on his left foot, if he is right-handed (the right foot touches or is near the middle of the lower leg), without shoes, eyes are closed, hands on the hips (without prior training). A lefty is standing on his right foot. While standing, balancing with a change in the position of the arms and legs is acceptable, followed by a return to its original position. The duration of the SB is measured using a stopwatch three times with an interval of 3 minutes. The maximum result is taken into account.

7. Body weight (MT - kg) is determined in light clothing, without shoes using floor scales.

8. Subjective health assessment (POPs) is carried out using a questionnaire of 29 questions. A printed questionnaire is given to the subject, who must emphasize the answer to each question. The total number of adverse responses can range from 0 to 29, and this value is included in the formula for determining biological age.

9. The Wexler Alphanumeric Test (TV) is performed using a standard protocol form. The task is to enter the characters corresponding to the numbers located in each cell into the empty cells for 90 seconds with maximum speed. The fill pattern is in the top row, which can be accessed constantly. The first 3 cells are filled during the briefing by the doctor-researcher, the next 7 cells are the subject under the supervision of the researcher as a training. After that, the stopwatch starts, and subsequent cells are filled in a row without gaps from left to right. The number of cells correctly filled in 90 s is taken into account. The number of correctly filled cells is the result included in the BV formula.

The dynamics of the difference between the biological and calendar age before and after the course of therapy in the Transfer Factor group and the Transfer Factor in combination with hypoxic effect is shown in Table 1.

Table 1 Transfer Factor Group Group “Transfer factor + hypoxic effect” Before After Δ Before After Δ Bio-age (years) (-3.8) ± 0.7 (-8.2) ± 0.7
P <0.001 4.4 + 0.3 ± 0.8 (-8.7) ± 0.8
P <0.001 9.0 Systolic Blood Pressure (mmHg) 134 ± 3.7 124 ± 2.1
P <0.05 10.0 147 ± 3.2 122 ± 1.8
P <0.001 25.0 Sample Stange (sec) 52 ± 2.8 66 ± 3,5
P <0.01 14.0 44 ± 2,4 72 ± 3,3
P <0.001 28.0

As can be seen from the table, before the course of therapy, the biological age in the first group was (-3.8) years, in the second - + 0.3 ± 0.83, after the treatment in the first group, this indicator decreased to (-8.2 ± 0.7, P <0.001) years, and in the second group to (-8.7 ± 0.75, P <0.001). In general, in the TF group, after the course of therapy, the biological age decreased by 4.4 years, while in the experimental group it decreased by 9 years. Thus, a more pronounced decrease in the values of biological age is observed as a result of the use of the immunocorrector “Transfer factor” in combination with hypoxic exposure.

When assessing systolic blood pressure (SBP), a significant decrease was detected in both groups, but in the experimental group it was 2.5 times more pronounced, which, of course, positively characterizes changes in the functional state of the cardiovascular system.

A statistically significant difference in the values of the Stange test (breath-holding test) in the groups indicates more pronounced improvements in the adaptive capabilities of the body of the patients of the experimental group.

Thus, the obtained results suggest that the use of a combination of the administration of the Transfer Factor drug and hypoxic exposure increases the effectiveness of TF in reducing biological age by potentiating the effects of TF against the background of increased nonspecific resistance of the body.

Example 1

Patient A., 56 years old. He suffers from type 2 diabetes for a long time, receives glucose-lowering therapy, fasting glycemia is not sufficiently controlled. Complaints: fatigue, thirst, sleep disturbance, irritability. When examined prior to the course of therapy: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is excessively expressed, musculoskeletal system without visible pathology, vesicular breathing in the lungs, a moist tongue, white skin plaque, abdomen on palpation is soft, painless, the liver is not enlarged. Body weight 80.0 kg, blood pressure 165/90 mm Hg, Stange test 30 sec, fasting glycemia 9.3 mmol / l, biological age + 9.9 years.

The patient received therapy corresponding to the proposed method. However, due to the presence of a concomitant pathology in the form of type 2 diabetes, I additionally received a Transfer-containing preparation - Transfer factor Glukoouch in a dose of at least 6 capsules per day. Scheme of hypoxic effects: the 1st and 2nd day the cycle consisted of 2 minutes of breathing GHS + 3 minutes of rest (breathing atmospheric air), for a session of 5 cycles; 3rd and 4th day cycle - 3 min + 3 min, for a session of 5 cycles; The 5th and 6th day - a break, the 7th day cycle - 3 min + 3 min, for the session 7 cycles, the 8th day cycle - 3 min + 3 min, for the session 9 cycles; The 9th day of the cycle - 5 min + 5 min, for the session 5 cycles, the 10th day of the cycle - 5 min + 5 min, for the session 6 cycles, then in the achieved mode up to 25 sessions.

After a course of therapy, no complaints; upon examination: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is excessively expressed, musculoskeletal system without visible pathology, vesicular breathing is observed in auscultation in the lungs, tongue is moist, clean, abdomen on palpation soft, painless, the liver is not enlarged. Body weight 76.0 kg, blood pressure 105/70 mm. Hg, Stange test 80 sec, fasting glycemia 5.9 mmol / l, biological age (-0.6) years.

Example 2

Patient L., 54 years old. The main diagnosis is persistent moderate asthma, endogenous form. Receives inhaled glucocorticosteroids (IGCS), bronchodilation therapy as needed, antibiotic therapy - in courses. Complaints: fatigue, the occurrence of asthma attacks up to 4-5 times a day, including at night, sleep disturbance. When examined prior to the course of therapy: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is satisfactorily expressed, the musculoskeletal system without visible pathology, vesicular hard breathing on the auscultation, wheezing on the forced expiration wheezing the tongue is moist, clean, the abdomen on palpation is soft, painless, the liver is not enlarged. Body weight 70.0 kg, blood pressure 130/90 mm Hg, Stange test 40 sec, VC 2970 ml, the use of short-acting bronchodilators up to 4 times a day daily, biological age +5.1 years.

The patient received therapy corresponding to the proposed method. However, due to the presence of a concomitant pathology in the form of bronchial asthma of an endogenous form, I additionally received the Transfer Factor Advance at a dose of at least 4 capsules per day. Scheme of hypoxic effects: on the 1st and 2nd day the cycle consisted of 3 min of HHS breathing + 3 min of rest (breathing atmospheric air), for a session of 5 cycles; 3rd and 4th day cycle - 3 min + 3 min, per session 7 cycles; 5th day cycle - 3 min + 3 min, for the session 9 cycles, 6th and 7th day - a break, 8th day cycle - 5 min + 5 min, for the session 5 cycles; 9th day cycle - 5 min + 5 min, per session 6 cycles, then in the achieved mode up to 25 sessions.

After a course of therapy, he did not actively complain, noted improvement in sleep (lack of night attacks), good performance. On examination: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is satisfactorily expressed, the musculoskeletal system without visible pathology, vesicular hard breathing is observed during auscultation in the lungs, no wheezing; the tongue is moist, clean, the abdomen on palpation is soft, painless, the liver is not enlarged. Body weight 70.0 kg, blood pressure 115/70 mm Hg, Stange test 80 sec, VC 3390 ml, the use of short-acting bronchodilators 1-2 times a day, biological age (-3.4) years.

Example 3

Patient C., 61 years old. A year ago, arterial hypertension was first detected, does not receive permanent antihypertensive therapy, and does not control blood pressure. Complaints of tinnitus, poor sleep, fatigue. When examined before a course of therapy: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is moderate, musculoskeletal system without visible pathology, vesicular breathing in the lungs, a moist tongue, white skin plaque at the root, abdomen on palpation soft, painless, the liver is not enlarged. Body weight 85.0 kg, blood pressure 175/115 mm Hg, Stange test 29 sec, static balancing time 3 sec, biological age +4.5 years.

The patient received therapy corresponding to the proposed method. However, due to the presence of a concomitant pathology in the form of type 2 diabetes, I additionally received a Transfer-containing preparation - Transfer factor Cardio in a dose of at least 6 capsules per day. Scheme of hypoxic effects: the 1st and 2nd day the cycle consisted of 2 minutes of breathing HHS + 3 minutes of rest (breathing atmospheric air), for a session of 5 cycles; 3rd and 4th day cycle - 3 min + 3 min, for a session of 5 cycles; 5th day - 3 min + 3 min, for the session 7 cycles, 6th and 7th day cycle - break, 8th day cycle - 3 min + 3 min, for the session 9 cycles; The 9th day of the cycle - 5 min + 5 min, for the session 5 cycles, the 10th day of the cycle - 5 min + 5 min, for the session 6 cycles, then in the achieved mode up to 25 sessions.

After a course of therapy, she has no complaints, notes the absence of tinnitus, normalization of sleep, fatigue does not bother. On examination: satisfactory condition, peripheral skin integument of physiological color and humidity, lymph nodes during palpation are not enlarged, subcutaneous fat is moderate, musculoskeletal system without visible pathology, vesicular breathing is observed in auscultation in the lungs, tongue is moist, clean, abdomen on palpation soft, painless, the liver is not enlarged. Body weight 82.0 kg, blood pressure 135/85 mm Hg, Stange test 69 seconds, static balancing time 13 seconds, biological age (-5.6) years.

Example 4

To assess the dose-dependent effect, three patients were prescribed TF therapy in various doses in combination with hypoxic exposure. The first patient received a dose of TF - 3 capsules per day, the second - 9 capsules per day, the third patient received 15 capsules per day, each in combination with hypoxic exposure.

Patients did not have a concomitant pathology, were comparable in age and sex, baseline biological age.

After the course of therapy, the following results were obtained: in the first case, the biological age decreased by 8.1 years, in the second - 8.9 years, in the third - by 8.3 years.

Indicators of biological age in patients before and after therapy with various dosages of the Transfer Factor are shown in Table 2.

table 2 A patient BV before therapy (years) BV after therapy (years) Δ (years) one -1.5 -9.6 8.1 2 -1.2 -10.1 8.9 3 -1.4 -9.7 8.3

The results obtained suggest that increasing the dose of more than 10 capsules of the “Transfer Factor” per day essentially does not increase the effectiveness of the combination “Transfer Factor in combination with hypoxic exposure."

Claims (2)

1. A method of reducing the biological age of a person, consisting in the fact that the patient is administered the immunocorrector "Transfer factor" five days a week for at least 6 weeks, characterized in that the immunocorrector is administered in combination with hypoxic exposure in a cyclically fractionated mode according to a scheme individually selected on the basis of the Stange test parameters, at a dose of 3-10 capsules per day. 2. The method according to claim 1, characterized in that use a hypoxic gas mixture with a concentration of O ₂ from 9% to 16%.